Wi beats top-line and bottom-line estimates; gives Q4 and reaffirms FY26 outlook

Wi beats top-line and bottom-line estimates; gives Q4 and reaffirms FY26 outlook

Wi Q3 earnings beat estimates with strong revenue growth.

Ionis Stock In Focus After Revenue Beat And Reaffirmed 2026 Outlook

Ionis Pharmaceuticals reported third quarter 2026 revenue of US$243 million compared with US$157 million a year earlier, with the quarterly net loss narrowing to US$110 million and full year 2026 revenue guidance reaffirmed at US$875 million to US$900 million. The mix of higher quarterly sales,…